• Using plan sponsor data from 2007-2009 for approximately
14 million beneficiaries, a 1 percentage point increase in GDR was associated with a 2.5% reduction in gross pharmacy costs. Holding total utilization constant, the reduction in gross pharmacy costs associated with a 1 percentage point GDR increase was 1.3%. • This study confirms that, in practice, prescription drug cost savings from GDR increases derive both from brand-to-generic conversions and from reductions in brand utilization.
What this study adds
O f the $2.3 trillion spent on health care in the United States in 2008, more than 10% ($234.1 billion) was for prescription drugs. 1 Yet, since 2003 annual increases in prescription drug expenditures have slowed considerably. This deceleration is attributed in large part to growth in the availability and use of generic drugs.
2,3 A recent report estimated that generics saved the U.S. health care system $824 billion from 2000 to 2009, including $139.6 billion in 2009. 4 These savings resulted from substantially lower drug prices. For instance in 2008, the average per prescription brand and generic drug prices in community pharmacies were $137.90 and $35.22, respectively. 5 Given the savings potential and robust pipeline, generic pharmaceuticals have become increasingly important for plan sponsors. Many elements of a pharmacy benefit, such as copayments, step therapy, and dispense-as-written penalties, are designed to encourage the utilization of generics over brands. To measure success in this regard, pharmacy benefit management companies (PBMs) and their clients often turn rate-the number of prescriptions filled PMPQ for brands with a chemically equivalent generic available. In addition to these absolute measures of utilization, 2 relative measures of generic drug use were created for each plan and quarter. The generic substitution ratio (GSR) was calculated as the number of generic drug claims divided by the sum of generic and MSB drug claims. The GDR was derived as the proportion of all claims filled as generic. For all pharmacy utilization metrics, claims were adjusted to 30-day equivalent prescriptions to account for the extended days supply associated with mailservice pharmacy use.
PMPQ measures of expenditures paid in total (gross), by members, and by plans (net of member cost share) were calculated from paid amounts listed on adjudicated pharmacy claims. As the key dependent variable employed in the models discussed below, gross pharmacy expenditure PMPQ was logtransformed in order to approximately normalize its skewed distribution and to allow for the presentation of GDR effects in terms of percentage changes in gross prescription drug costs.
Econometric Analysis
Linear fixed effects models were estimated to examine the association of GDR with gross pharmacy costs. This econometric technique makes use of within-subject variation only to identify the effects of included regressors. Consequently, the effects of all observed and unobserved characteristics that do not vary over time, including potential confounders, are removed from the analysis. 9 Stated differently, the analysis examined plan-specific quarterly changes in gross pharmacy costs as related to quarterly changes in GDR. Two models were specified. In both, the dependent variable was log-transformed gross pharmacy costs PMPQ, and the independent variables were GDR, demographic characteristics (described previously), and a vector of quarterly time dummy variables that controlled for time-varying characteristics common to all clients (e.g., pharmaceutical pipeline, price inflation). The 2 models differed in that one included an additional independent variable, total drug utilization (i.e., total number of 30-day adjusted prescriptions PMPQ). Results of the 2 models were compared in order to decompose pharmacy cost savings from GDR increases into those from brand-to-generic conversions versus those from decreases in brand utilization. All analyses were conducted using Stata/MP 11.1 (StataCorp, College Station TX) and in accordance with privacy standards. Table 1 presents demographic characteristics, pharmacy utilization, and costs for each quarter for the sample of 548 employers over the 3-year study period (2007) (2008) (2009) to the generic dispensing ratio (GDR), the proportion of all prescriptions dispensed as a generic. GDR has become a key performance metric for the Centers for Medicare & Medicaid Services, as well as for managed care. 2, 6 Moreover, innovations in plan design and educational interventions are often considered because of their anticipated impact on GDR.
■■ Results
Despite the widespread adoption of GDR as an indicator of pharmacy benefit performance, no peer-reviewed published report has analyzed the financial savings that payers realize with increases in GDR. In annual pharmacy trend reports, PBMs generally report that a 1% increase in GDR yields a savings of 1% to 2% in total pharmacy expenditures. 7, 8 One might conclude that because the relationship between GDR and gross pharmacy cost is defined by a mathematical equation, it is therefore easily calculable and does not warrant peerreviewed publication. Indeed, given a starting GDR value and known relative prices for brands and generics, one can derive the percentage change in drug expenditures resulting from an absolute change in GDR. This calculation is accurate, however, only under an assumption that total utilization remains constant-that is, assuming GDR changes result exclusively from brand-to-generic conversion. Of course, GDR can also increase because of lower brand use without a compensating increase in generic use (i.e., decreasing denominator). Therefore, the actual savings realized from increases in GDR are not readily derived without information on the absolute levels of brand and generic utilization.
In this study, we estimated the relationship between GDR and gross pharmacy expenditures and the extent to which savings from increases in GDR were due to brand-to-generic conversion versus net reductions in brand use.
■■ Methods Study Sample and Variable Construction
An analytical dataset was constructed using paid pharmacy claims from 548 self-insured employers covering nearly 14 million members from January 1, 2007, through December 31, 2009. All included plan sponsors insured a minimum of 500 members and had both retail and mail-service pharmacy benefits managed by CVS Caremark throughout the entire 3-year study period. The claims data for each plan were aggregated into calendar quarters, resulting in a total of 6,576 observations (i.e., 548 × 12). Measures of plan membership demographics were generated, including percent male, proportion in each of 5 age groups in years (0-11, 12-18, 19-39, 40-64, and 65 or older), and the concentration of individuals residing in each of 5 geographic regions (West, Midwest, Northeast, South, and other/unknown).
Several drug utilization variables were constructed: generic utilization rate-the number of generic prescriptions filled per eligible plan member per quarter (PMPQ); brand utilization rate-the number of brand prescriptions filled PMPQ; singlesource brand (SSB) utilization rate-the number of prescriptions filled PMPQ for brands without a chemically equivalent generic available; and multisource brand (MSB) utilization In recent years, generic drug use has surged largely due to the confluence of both supply-and demand-side factors. Increased availability of generics following brand drug patent expirations, legislation that allows (or, in some states, requires) pharmacies to automatically substitute a generic for a brand, and some community pharmacy networks that have financial incentives such as higher dispensing fees for generic drugs and/or more generous maximum allowable cost (MAC) prices for generic drugs have been the dominant supply-side drivers that have contributed to increased generic utilization. On the demand side, PBMs and pharmacy plan sponsors have adopted increasingly aggressive benefit designs and interventions to encourage generic drug use, examples of which include multiple formulary tiers, higher member cost shares for brands, deductibles, step therapy, and prior authorization.
10 As a result of these market conditions, generic drugs are dispensed nearly 98% of the time when both a brand and generic drug with the same active ingredient(s) are available.
With GSR at 98%, SSBs represent more than 95% of all brand drug prescriptions dispensed. Consequently, incremental improvements in generic use are predominantly the result of either an SSB becoming generically available or a patient or physician actively choosing a generic drug over a therapeutically interchangeable brand with a different active ingredient. The economic incentives embedded in pharmacy benefit designs have proven successful in dissuading MSB use, but results are mixed for SSB-to-generic conversions. Indeed, pharmacy benefit designs that impose barriers to access or differentially increase brand drug out-of-pocket costs do so with some risk of reducing appropriate use.
11 The present study highlights the fact that GDR, the preferred relative measure of generic drug utilization, if examined apart from its absolute utilization components, masks the extent to which this reduction may be occurring.
The fixed-effects modeling approach allows for a more accurate evaluation of changes in GDR and pharmacy costs over time, with adequate accounting for population shifts in demographics, utilization, and secular changes (in our case, with the inclusion of variables for calendar quarter). This econometric technique uncovers an association not otherwise suggested by the simple descriptive results presented in Table 1 .
Limitations
Despite the general strengths of the fixed-effects modeling approach, the present study is limited in at least 2 ways. First, the estimated impact of GDR on gross pharmacy costs (with and without control for overall drug utilization) may be biased despite the use of fixed effects modeling, which controls for time-invariant confounders. Since total cost is the product of utilization and price, brand and generic drug prices are likely correlated with both GDR (via price elasticity of demand) and total pharmacy costs. Thus, to the extent that drug prices changed over time during the study period (beyond the secular price trends common to all clients, controlled for by the quarterly time indicators) the impact of GDR on gross pharmacy Table 2 presents coefficient estimates from the 2 models of log-transformed gross pharmacy costs. In Model 1, a 1 percentage point increase in GDR was significantly (P < 0.001) associated with a reduction of 2.5% in gross pharmacy costs, controlling for demographics and time trends. When total utilization PMPQ was added and held constant in Model 2, the reduction in pharmacy costs associated with a 1 percentage point increase in GDR was 1.3% (P < 0.001).
■■ Discussion
Increases in GDR are associated with reductions in overall pharmacy expenditures for 2 reasons: brand-to-generic conversion and reduced brand use (not otherwise substituted with a generic). Under the former scenario, the number of generic prescriptions increases (i.e., the GDR numerator is increasing) with an equal decrease in the number of brand prescriptions (i.e., the GDR denominator is unchanged). Total drug costs decline in this scenario because prices are lower for generic drugs than for their branded counterparts. GDR can also increase, however, when the number of brand prescriptions is reduced without an equal change in generic prescriptions (i.e., the GDR denominator is decreasing). Pharmacy costs decline in this scenario because fewer total prescriptions are filled.
The present study was an empirical analysis of the relationship between GDR and gross pharmacy costs. Specifically, changes in these metrics were examined over time to quantify GDR's association with drug expenditures and to decompose this relationship into its 2 components. Among the sample of 548 employers from 2007 through 2009, a 1 percentage point increase in GDR was associated with a reduction of 2.5% in gross pharmacy expenditures. After adjusting for total utilization, an approach that isolated the brand-to-generic conversion portion of the effect, a 1 percentage point increase in GDR was associated with a reduction of 1.3% in gross pharmacy expenditures. This finding suggests that roughly one-half (1.3% of 2.5%) of the savings realized in practice from increasing GDR is due to the price discounts enjoyed with brand-to-generic conversions. The other half of pharmacy cost savings from rising GDR can be attributed to reductions in brand use not otherwise replaced by generic utilization.
costs may be over-or understated in the present analysis. Additionally, other time-varying confounders, such as changes to formularies and introduction of step-therapy or prior authorization programs, were not measured in this study and could have affected study results. Second, while we speculate that reductions in total utilization may represent reductions in appropriate medication use, other explanations are plausible. For instance, patients facing a step-therapy or dispenseas-written penalty may have obtained samples from their physicians, selected an over-the-counter medication instead, or paid for the desired prescription in full without using their prescription drug insurance benefit. more than one-half of the savings was derived from the lower drug prices enjoyed with brand-to-generic conversions. The remaining savings, however, can be attributed to reduced brand drug utilization. The critical challenge in designing pharmacy benefits is to find the optimal balance between access to appropriate medications and cost management.
13
Pharmacy benefit managers and plan sponsors should exercise care to ensure that increases in GDR are not from discontinuation of or reduced adherence to appropriate therapy.
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